The mean length of the preclinical detectable phase (PCDP) of open-angle glaucoma is estimated to be over 10 years, according to a study published online Nov. 23 in JAMA Ophthalmology. A Northwestern ...

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

FORT LAUDERDALE, Florida — Gum disease with recent tooth loss has been linked to the risk for primary open-angle glaucoma, according to findings from a survey of some 40,000 male health professionals.

A licensing agreement between SERI and Eyexora Global has launched Y.ora Vision, a new ophthalmic medical device company.

Please provide your email address to receive an email when new articles are posted on . “Relaxation techniques have been reported to reduce IOP and improve neuroendocrine regulation of the ciliary ...

Purpose To establish the age- and sex-specific prevalence of open-angle glaucoma (OAG) subsuming pseudoexfoliation (PEX) in the city of Reykjavik. Methods Participants 50 years of age and older who ...

According to a new study, migraine is associated with a higher risk of open-angle glaucoma compared with patients with no migraine. While the exact pathophysiology behind migraine is unknown, the ...

Nova Eye Medical Ltd (($ELXMF)) announced an update on their ongoing clinical study. Study Overview: Nova Eye Medical Ltd is conducting a clinical ...

Omlonti is a relatively selective EP2 receptor agonist designed to increase aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways. The Food and Drug ...

Y.ora Vision, Inc., a new ophthalmic medical device company and spoke company of Eyexora, today announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and ...

Sight Sciences’ management is scheduled to present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 am PT / 11:20 am ET. Sight Sciences’ management is scheduled to ...